Bioorthogonal chemistry for prodrug activation in vivo
Prodrugs have emerged as a major strategy for addressing clinical challenges by improving
drug pharmacokinetics, reducing toxicity, and enhancing treatment efficacy. The emergence …
drug pharmacokinetics, reducing toxicity, and enhancing treatment efficacy. The emergence …
Click and release: bioorthogonal approaches to “on-demand” activation of prodrugs
Prodrug approaches represent an excellent solution to certain pharmaceutical issues
commonly encountered in the drug discovery and development process. Along this line, the …
commonly encountered in the drug discovery and development process. Along this line, the …
Supramolecular prodrugs based on host–guest interactions
WC Geng, JL Sessler, DS Guo - Chemical Society Reviews, 2020 - pubs.rsc.org
Classic prodrug strategies rely on covalent modification of active drugs to provide systems
with superior pharmacokinetic properties than the parent drug and facilitate administration …
with superior pharmacokinetic properties than the parent drug and facilitate administration …
General Strategy for Integrated Bioorthogonal Prodrugs: Pt(II)-Triggered Depropargylation Enables Controllable Drug Activation In Vivo
T Sun, T Lv, J Wu, M Zhu, Y Fei, J Zhu… - Journal of Medicinal …, 2020 - ACS Publications
Bioorthogonal decaging reactions for controllable drug activation within complex biological
systems are highly desirable yet extremely challenging. Herein, we find a new class of Pt (II) …
systems are highly desirable yet extremely challenging. Herein, we find a new class of Pt (II) …
The expanding role of prodrugs in contemporary drug design and development
J Rautio, NA Meanwell, L Di… - Nature reviews drug …, 2018 - nature.com
Prodrugs are molecules with little or no pharmacological activity that are converted to the
active parent drug in vivo by enzymatic or chemical reactions or by a combination of the two …
active parent drug in vivo by enzymatic or chemical reactions or by a combination of the two …
Towards the next generation of biomedicines by site-selective conjugation
QY Hu, F Berti, R Adamo - Chemical Society Reviews, 2016 - pubs.rsc.org
Bioconjugates represent an emerging class of medicines, which offer therapeutic
opportunities overtaking those of the individual components. Many novel bioconjugates …
opportunities overtaking those of the individual components. Many novel bioconjugates …
Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy
Prodrugs are chemically modified drug molecules that are inactive before administration.
After administration, they are converted in situ to parent drugs and induce the mechanism of …
After administration, they are converted in situ to parent drugs and induce the mechanism of …
Prodrugs: design and clinical applications
J Rautio, H Kumpulainen, T Heimbach… - Nature reviews Drug …, 2008 - nature.com
Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/or
chemical transformation in vivo to release the active parent drug, which can then exert the …
chemical transformation in vivo to release the active parent drug, which can then exert the …
Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery
Smart drugs, such as antibody‐drug conjugates, for targeted therapy rely on the ability to
deliver a warhead to the desired location and to achieve activation at the same site. Thus …
deliver a warhead to the desired location and to achieve activation at the same site. Thus …
Current prodrug design for drug discovery
Prodrugs are inactive compounds which are metabolized either chemically or enzymatically
in a controlled or predictable manner to the parent active drug inside the body. Prodrugs can …
in a controlled or predictable manner to the parent active drug inside the body. Prodrugs can …